US FDA Warns Syntec Pharma Against Sourcing APIs From Import-Alerted Suppliers
Import alerts, warning letters failed to deter company from importing adulterated drug substances. Syntec also cited for cross-contamination, cleaning lapses.
You may also be interested in...
FlexBiosys wins award; others to follow. New capacity may also benefit manufacture of monoclonal antibodies and cell and gene therapies.
US FDA is looking at risk-based approach for reporting changes in out-of-stock components such as plastic bioreactor bags, filters and tubing sets that are in short supply.
Summary judgment puts 20-year-old effort to define ‘inordinate’ out-of-state drug compounding back on slow track.